GlassScriptPhysician profile
Martiza Dotres-Martinez
NPI 1447527254
$4,910.59
in general payments reported to CMS, 2019-2025
35 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $305 · 2021: $462 · 2022: $956 · 2023: $1,149 · 2024: $632 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $991.75 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $589.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $495.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $453.84 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $427.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $338.30 | 2022-2025 | |
| Abbvie INC. | $205.13 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $156.51 | 2019-2022 | |
| Pfizer INC. | $123.21 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.98 | 2020-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.46 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $104.46 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $104.00 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $102.57 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $67.20 | 2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.38 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.61 | 2019 | |
| Dexcom, INC. | $43.83 | 2022 | |
| Harmony Biosciences LLC | $40.96 | 2023 | Wakix |
| Astellas Pharma US INC | $40.35 | 2019-2022 | |
| Eisai INC. | $34.36 | 2021-2022 | |
| Medtronic, INC. | $31.42 | 2023 | Interstim |
| Idorsia Pharmaceuticals US INC | $28.15 | 2022 | |
| Seqirus USA INC | $23.07 | 2025 | Fluad, Flucelvax |
| Ultragenyx Pharmaceutical INC. | $20.16 | 2021 | |
| Photonicare INC | $19.90 | 2025 | Otosight Middle Ear Scope |
| Paratek Pharmaceuticals, INC. | $18.20 | 2025 | Nuzyra |
| Agios Pharmaceuticals, INC. | $15.85 | 2025 | Pyrukynd |
| Phadia US INC. | $15.39 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.11 | 2022 | |
| Grt US Holding, INC. | $14.79 | 2021 | |
| Shield Therapeutics INC | $14.54 | 2023 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $13.69 | 2021 | |
| Cvrx, INC. | $12.84 | 2025 | Barostim Neo System |
| Kowa Pharmaceuticals America, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martiza Dotres-Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.